SCHEMBL711751

SCHEMBL711751

Cc1cc(S(=O)(=O)N(C)C)ccc1Br

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
LMNA P02545 4/20 0.49
PKM P14618 3/20 0.49
ALDH1A1 P00352 9/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
VCAM1 P19320 1/20 0.44
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
THRB P10828 1/20 0.42
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369561 0.85 MAPT (0.57) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL19255842 0.82 LMNA (0.57) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL5623940 0.81 ALDH1A1 (0.60) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL830828 0.80 LMNA (0.51) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL16492176 0.80 HTR2A (0.59) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL5524384 0.79 ALDH1A1 (0.50) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL23203435 0.79 MAPT (0.60) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL30783237 0.79 MAPT (0.60) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL30305918 0.79 MAPT (0.60) MAPTLMNAPKMALDH1A1MEN1
SCHEMBL2113235 0.79 MAPT (0.60) MAPTLMNAPKMALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3757093-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-12-30 EP disclosed
EP-2975030-B1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2020-07-15 EP disclosed
US-9499553-B2 Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-22 US disclosed
US-9499553-B2 Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-22 US disclosed
US-9493478-B2 Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same YUHAN CORPORATION (KR) 2016-11-15 US disclosed
US-20160151337-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS GRUENENTHAL GMBH (DE) 2016-06-02 US disclosed
US-20160151337-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS GRUENENTHAL GMBH (DE) 2016-06-02 US disclosed
US-20160151337-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS GRUENENTHAL GMBH (DE) 2016-06-02 US disclosed
EP-2975030-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2016-01-20 EP disclosed
US-20160002251-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-07 US disclosed
WO-2010055005-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
US-7709488-B2 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG (DE) 2010-05-04 US disclosed
CN-100422182-C Imidazopyridine derivatives as inducible NO-synthase inhibitors ALTANA PHARMA AG (DE) 2008-10-01 CN disclosed
EP-1670796-B1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS NYCOMED GMBH (DE) 2008-06-25 EP disclosed
US-20080021039-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG 2008-01-24 US disclosed
US-7279488-B2 Imidazopyridine-derivatives as inducible no-synthase inhibitors NYCOMED GMBH (DE) 2007-10-09 US disclosed
US-20060293302-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG (DE) 2006-12-28 US disclosed
CN-1856495-A Imidazopyridine Derivatives as Inducible NO-Synthase Inhibitors ALTANA PHARMA AG (DE) 2006-11-01 CN disclosed
EP-1670796-A1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS ALTANA Pharma AG (DE) 2006-06-21 EP disclosed
WO-2005030770-A1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS ALTANA PHARMA AG (DE) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293302-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors NOS2, NOS1, NOS3 MAPT 4138/4885LMNA 4549/4885PKM 2251/4885
US-20080021039-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors NOS2, NOS1, NOS3 MAPT 4138/4885LMNA 4549/4885PKM 2251/4885
US-20160002251-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME SLC9A5, SLC5A2, SLC5A1 MAPT 2178/4885LMNA 3282/4885PKM 1602/4885
US-20160151337-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS AADAC, PRRC2C, PRRC2A MAPT 2886/4885LMNA 2660/4885PKM 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.